acetazolamide has been researched along with Aneurysm, Ruptured in 4 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Aneurysm, Ruptured: The tearing or bursting of the weakened wall of the aneurysmal sac, usually heralded by sudden worsening pain. The great danger of a ruptured aneurysm is the large amount of blood spilling into the surrounding tissues and cavities, causing HEMORRHAGIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prediction of cerebral infarction due to vasospasm (VS) following aneurysmal subarachnoid haemorrhage (SAH) was investigated using acetazolamide-activated (A-A) N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) single photon emission computed tomography (SPECT) in 79 SAH patients." | 7.68 | Prediction of cerebral infarction due to vasospasm following aneurysmal subarachnoid haemorrhage using acetazolamide-activated 123I-IMP SPECT. ( Funakoshi, T; Kimura, T; Shinoda, J, 1993) |
| "Prediction of cerebral infarction due to vasospasm (VS) following aneurysmal subarachnoid haemorrhage (SAH) was investigated using acetazolamide-activated (A-A) N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) single photon emission computed tomography (SPECT) in 79 SAH patients." | 3.68 | Prediction of cerebral infarction due to vasospasm following aneurysmal subarachnoid haemorrhage using acetazolamide-activated 123I-IMP SPECT. ( Funakoshi, T; Kimura, T; Shinoda, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CC | 1 |
| Kuwana, N | 1 |
| Ito, S | 1 |
| Yokoyama, T | 1 |
| Kanno, H | 1 |
| Yamamoto, I | 1 |
| Kimura, T | 1 |
| Shinoda, J | 1 |
| Funakoshi, T | 1 |
| Yoshida, K | 1 |
| Nakamura, S | 1 |
| Watanabe, H | 1 |
| Kinoshita, K | 1 |
| George, B | 1 |
| Mourier, KL | 1 |
| Lot, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| C-arm Cone Beam CTA and CTP With Acetazolamide Challenge in Aneurysmal Subarachnoid Hemorrhage: Evaluating Predictability for Early Ischemia in Cerebral Vasospasm[NCT03377049] | Phase 4 | 11 participants (Actual) | Interventional | 2019-07-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical neurological deterioration not attributable to other causes, mores specifically not due to re-bleeding, hydrocephalus, or metabolic changes. (NCT03377049)
Timeframe: Day 1-14 during the hospitalization
| Intervention | Participants (Count of Participants) |
|---|---|
| Acetazolamide Challenge | 2 |
Using perfusion map values, relative percent change will be calculated (NCT03377049)
Timeframe: pre and post perfusion during imaging procedure, up to an hour
| Intervention | percent change (Mean) |
|---|---|
| Acetazolamide Challenge | 19.785 |
Using perfusion map values, relative percent change will be calculated (NCT03377049)
Timeframe: pre and post perfusion during imaging procedure, up to an hour
| Intervention | percent change (Mean) |
|---|---|
| Acetazolamide Challenge | 21.659 |
The data that will be statistically compared is the pre-diamox perfusion in comparison to the post-diamox perfusion. A statistically significant change increase in CBF represents an appropriate response to Diamox. Lack of change in CBF or decrease in CBF could be suggestive of potential for developing vasospasm. (NCT03377049)
Timeframe: pre and post perfusion during imaging procedure, up to an hour
| Intervention | percent change (Mean) |
|---|---|
| Acetazolamide Challenge | 20.722 |
1 trial available for acetazolamide and Aneurysm, Ruptured
| Article | Year |
|---|---|
Cerebral haemodynamics in patients with hydrocephalus after subarachnoid haemorrhage due to ruptured aneurysm.
Topics: Acetazolamide; Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Brain; Cerebral Ventricles; Cereb | 2003 |
3 other studies available for acetazolamide and Aneurysm, Ruptured
| Article | Year |
|---|---|
Prediction of cerebral infarction due to vasospasm following aneurysmal subarachnoid haemorrhage using acetazolamide-activated 123I-IMP SPECT.
Topics: Acetazolamide; Adult; Aged; Aged, 80 and over; Amphetamines; Aneurysm, Ruptured; Brain; Cerebral Inf | 1993 |
Early cerebral blood flow and vascular reactivity to acetazolamide in predicting the outcome after ruptured cerebral aneurysm.
Topics: Acetazolamide; Aneurysm, Ruptured; Blood Flow Velocity; Brain; Brain Ischemia; Glasgow Coma Scale; H | 1996 |
[Cerebral blood flow in the determination of vasospasm and surgical decision].
Topics: Acetazolamide; Aneurysm, Ruptured; Cerebrovascular Circulation; Humans; Intracranial Aneurysm; Ische | 1992 |